You searched for fludarabine - Page 5 of 8

ASH 2020: Dr. Paul Barr on Combining Rituximab with BTK Inhibitors for Treatment of Chronic Lymphocytic Leukemia (CLL)

April 30, 2021

Dr. Paul Barr discusses which BTK inhibitor works best in combination with rituximab. At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Paul Barr, an Associate Professor of Medicine at the Wilmot Cancer Institute in Rochester, NY. They discussed the interchange between various BTK inhibitors and rituximab.

ASH 2020: Dr. Adrian Wiestner Discusses the Importance of Test Before Treat™ Predictive and Prognostic Biomarker Testing in Patients with Chronic Lymphocytic Leukemia (CLL)

March 11, 2021

At the American Society of Hematology’s (ASH) 2020 conference, there was research on looking at the genome of CLL and how different genetic markers might have predictive and value. Dr. Brian Koffman, Chief Medical Officer and Executive Vice President of CLL Society, interviewed Dr. Adrian Wiestner, a senior investigator at the National Institutes of Health in Bethesda, Maryland. They discuss why it is important for all CLL patients to receive genetic testing before receiving any new therapies, especially chemotherapy.

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

January 29, 2021

As the science of chronic lymphocytic leukemia has advanced, we have learned much more detailed information about its biology and the specific chromosomes, genes, and proteins that contribute to the disease. Checking for specific abnormalities in chromosomes and genetic variants can help doctors evaluate a patient’s prognosis and predict what treatments might work best.

Ask The Doctor Q4 2020: CAR-T Edition

December 15, 2020

Dr. Richard Furman of Weill-Cornell Medical College answers readers’ questions submitted to the CLL Society.

My MRD-Negative Journey Meant a New Beginning

September 17, 2020

By Keith Seagull – Patient Updated 10/3/2020: “I am happy to report that as of 9/30/2020 my Flow Cytometry Report has found no evidence of residual/recurrent chronic lymphocytic leukemia. That means

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

September 10, 2020

The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr. Koffman’s ASH 2019 interview with Dr. Neil Kay showing that five-year data continue to yield evidence of the superiority of ibrutinib to chemoimmunotherapy for most CLL patients. To understand the powerful impact of this evidence on best practice and learn the subtleties, click here.

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

June 24, 2020

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

ASH 2019: Dr. Chaitra Ujjani on Real World Prescribing for Chronic Lymphocytic Leukemia (CLL) and Why Expert Care is Critical

March 30, 2020

At ASH 2019 Dr. Chaitra Ujjani discusses real world prescribing for CLL and why expert care is so critical.

ASH 2018: Dr. Wiestner on the Immune System in CLL (chronic lymphocytic leukemia)

October 7, 2019

Dr. Adrian Wiestner of the National Institutes of Health has been researching the immune system in chronic lymphocytic leukemia for many years. We know that infections and second cancers are a

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: fludarabine – Page 5

ASH 2020: Dr. Paul Barr on Combining Rituximab with BTK Inhibitors for Treatment of Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Adrian Wiestner Discusses the Importance of Test Before Treat™ Predictive and Prognostic Biomarker Testing in Patients with Chronic Lymphocytic Leukemia (CLL)

iwCLL 2019: Dr. Nicole Lamanna on Biomarker Testing for Chronic Lymphocytic Leukemia (CLL)

Ask The Doctor Q4 2020: CAR-T Edition

My MRD-Negative Journey Meant a New Beginning

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

ASH 2019: Dr. Chaitra Ujjani on Real World Prescribing for Chronic Lymphocytic Leukemia (CLL) and Why Expert Care is Critical

ASH 2018: Dr. Wiestner on the Immune System in CLL (chronic lymphocytic leukemia)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT